Don't Just Read the News, Understand It.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Eid
World Cup
Artificial Intelligence
Donald Trump
Social Media
Elon Musk
Stock Markets
Education
Immigration
European Union
Soccer
Instagram
Published • loading... • Updated

Regeneron Pharmaceuticals (NASDAQ:REGN) Lowered to "Hold" Rating by Royal Bank of Canada

Summary by marketbeat.com
Royal Bank of Canada downgraded Regeneron Pharmaceuticals from an "outperform" rating to a "sector perform" rating and set a $662.00 price target for the company. in a research note on Friday.

2 Articles

All
Left
Center
1
Right
marketbeat.commarketbeat.com
Center

Regeneron Pharmaceuticals (NASDAQ:REGN) Lowered to "Hold" Rating by Royal Bank of Canada

Royal Bank of Canada downgraded Regeneron Pharmaceuticals from an "outperform" rating to a "sector perform" rating and set a $662.00 price target for the company. in a research note on Friday.

Read Full Article
gurufocus.comgurufocus.com

Royal Bank of Canada (RY) Downgraded Amid Dim Outlook

National Bank has revised its rating for Royal Bank of Canada (RY), downgrading it from "Outperform" to "Sector Perform." The bank also adjusted its price targe

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

gurufocus.com broke the news in on Friday, May 30, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Royal Bank of Canada

Royal Bank of Canada

Canada

Canada

News
For You
SearchBlindspotLocal